reptides › weight loss › cagrisema

cagrisema

semaglutide + cagrilintide. first fixed-dose GLP-1 + amylin combo. FDA review underway 2026.

tier B · weight loss · 23.0% REDEFINE-1 phase 3

verdict

semaglutide + cagrilintide. the first fixed-dose GLP-1 + amylin combo. NDA filed December 2025, expected FDA decision late 2026.

if you're asking whether cagrisema beats tirzepatide — no, on the head-to-head data. REDEFINE-1 produced 22.7% weight loss in cagrisema arm vs 16.1% for semaglutide alone and 11.8% for cagrilintide alone. the second-deepest phase 3 obesity number ever recorded. then REDEFINE-4 (Feb 2026) put cagrisema directly against tirzepatide 15 mg and cagrisema lost (23.0% vs 25.5%), missing its non-inferiority primary endpoint. it works, it works very well, and tirzepatide keeps the crown.

if you're asking about access before approval — cagrisema is investigational and not on an FDA bulk pathway for compounding. lawful US pharmacy access does not exist outside clinical trials before approval. vendor 'cagrisema' is gray-market research supply with no identity, purity, or dose-response data behind the dose being sold, not a regulatory workaround. expect an FDA decision in late 2026.

if you came in worried about side effects vs semaglutide alone — GI side effects (79.6% in REDEFINE-1) run higher than semaglutide alone. the second mechanism is genuinely additive on weight loss, but it's additive on the symptom side too. the trial dropout pattern reflects this. expect rebound on discontinuation. same chronic-medication model as the GLP-1 class.

based on published evidence and disclosed clinical practice. not medical advice. dose and protocol conversations belong with a clinician.

why B-tier

B-tier because the drug is not FDA-approved yet. clinical evidence is drug-grade: phase-3 program across 4,600 patients, NEJM, NDA filed. S is reserved for compounds with a decision issued. on FDA approval (expected late 2026) this moves to S. could also move up if REDEFINE-11 or higher-dose escalation finally hits the 25% novo originally targeted.

the core tension

the biggest name in weight-loss peptides that does not yet have FDA approval. 22.7% weight loss across 3,400 patients in REDEFINE-1, one of the best efficacy profiles ever published. novo's internal target was 25%. REDEFINE-4 came in behind tirzepatide (23.0% vs 25.5%), and the NDA is still months from a decision. a real drug in the final stretch, sitting in B-tier only because it is not approved yet.

what it is

fixed-dose combination of semaglutide (the GLP-1 in Ozempic and Wegovy) and cagrilintide (a long-acting amylin analog). both at 2.4 mg in a dual-chamber pen, once-weekly subcutaneous injection. novo filed the NDA on december 18, 2025. not yet FDA-approved.

what it does

hits two appetite pathways at once. semaglutide slows gastric emptying and kills post-meal hunger via the hindbrain. cagrilintide binds amylin and calcitonin receptors in the area postrema and reinforces meal-related satiety. in REDEFINE-1 the combo produced 22.7% weight loss vs 16.1% for semaglutide alone and 11.8% for cagrilintide alone.

origin

novo nordisk, REDEFINE program 2020 to 2025. 4,600+ patients across REDEFINE-1 (obesity, n=3,417), REDEFINE-2 (T2D, n=1,206), and REDEFINE-4 (head-to-head vs tirzepatide 15 mg). REDEFINE-1 published in NEJM, june 2025.

why researchers are interested

bariatric-adjacent weight loss from a weekly shot. the average patient drops 54 pounds off a 240-pound start. in REDEFINE-1, 60% of cagrisema patients hit at least 20% body-weight loss; 40.4% hit at least 25%. for readers who already tolerate semaglutide and want more, the second mechanism is genuinely additive, not rebranded GLP-1.

does it work

yes. with a caveat that matters. the data is real. 22.7% weight loss across 3,400 patients, NEJM, NDA filed december 2025. second-highest weight-loss number ever recorded in a phase-3 obesity trial, behind only retatrutide. the catch is REDEFINE-4. head-to-head against tirzepatide 15 mg, cagrisema lost (23.0% vs 25.5%) and missed its non-inferiority primary endpoint in february 2026. it works, it works very well, and it is still the number-two drug in its class. GI side effects (79.6% in REDEFINE-1) run higher than semaglutide alone. cagrisema is investigational and not on an FDA bulk pathway for compounding, so lawful US pharmacy access does not exist outside trials before approval. vendor versions are gray-market research supply, not a workaround. expect an FDA decision in late 2026. expect rebound on discontinuation. expect tirzepatide to keep the crown.

claims vs the data

  • 22.7% mean weight loss at 68 weeks (REDEFINE 1) — supported — Primary endpoint in the 3,417-patient phase 3 trial, published in NEJM June 2025. Trial product estimand. Treatment policy estimand was 20.4%. Both significantly superior to placebo, semaglutide monotherapy, and cagrilintide monotherapy.
  • superior to semaglutide monotherapy for weight loss — supported — REDEFINE 1 included a semaglutide-alone arm (16.1% weight loss) and cagrilintide-alone arm (11.8%). Cagrisema at 22.7% was significantly superior to both, supporting a real combination effect while stopping short of proving synergy beyond additivity.
  • comparable to tirzepatide for weight loss — contradicted — REDEFINE 4 (n=809, 84 weeks) directly compared cagrisema 2.4/2.4 vs tirzepatide 15mg. Cagrisema: 23% weight loss. Tirzepatide: 25.5%. Tirzepatide won the head-to-head. Marketing claim of 'superior to existing therapies' is overreach, the data show parity at best.
  • the first GLP-1 + amylin fixed-dose combination — supported — True as of filing. This is the first time these two mechanisms (GLP-1 agonism and amylin analog) have been co-formulated and filed for FDA approval as a single product.
  • improves glycemic control in T2D patients — supported — REDEFINE 2 (n=1206, T2D patients): 73.5% of cagrisema patients achieved HbA1c ≤6.5% vs 15.9% placebo. 13.7% weight loss. Both endpoints clinically meaningful.
  • side effect profile is comparable to single-agent GLP-1s — partially true — GI adverse events 79.6% on cagrisema vs 39.9% placebo in REDEFINE 1, higher than semaglutide monotherapy in published trials. Discontinuation rates were still low (5.9% cagrisema vs 3.5% placebo). Real but manageable. Adding amylin does increase GI side effect burden.
  • CagriSema has already beaten tirzepatide — contradicted — CagriSema has strong late-stage evidence, but the dominance claim is not settled by the current public record. The right frame is promising phase-3 combination therapy, not approved best-in-class replacement.

key facts

  • molecular formula: semaglutide (C187H291N45O59) + cagrilintide (C194H312N54O59S2)
  • molecular weight: 4113.6 Da (semaglutide) + 4409.0 Da (cagrilintide)
  • amino acids: 31 + 37
  • half-life: ~168 hours (once-weekly dosing, both components)
  • type: fixed-dose GLP-1 + amylin analog combination
  • CAS: 910463-68-2 / 1415456-99-3
  • 22.7% REDEFINE 1 weight loss at 68 weeks
  • 13.7% REDEFINE 2 weight loss (T2D patients)
  • Dec 2025 NDA filed with FDA
  • 2026 expected FDA decision

frequently asked questions

What is cagrisema?

Cagrisema is an investigational combination drug from Novo Nordisk containing two peptides: cagrilintide (a long-acting amylin analog) and semaglutide (the GLP-1 agonist behind Ozempic and Wegovy). It pairs two complementary appetite-regulation mechanisms in a single weekly injection.

What does cagrisema do?

Cagrisema targets two appetite pathways simultaneously: GLP-1 (satiety and delayed gastric emptying) and amylin (meal-associated satiety and glucagon suppression). Phase 3 REDEFINE data show weight loss greater than semaglutide or cagrilintide alone, while REDEFINE 4 showed tirzepatide remained stronger head-to-head.

How is cagrisema typically administered?

Cagrisema is administered as a once-weekly subcutaneous injection in clinical trials. Dosing titration follows a schedule similar to Wegovy, starting at a low dose and escalating over several months. The drug is not yet commercially available; final approved dosing will be determined by regulatory review.

What are the side effects of cagrisema?

Reported side effects in trials are primarily gastrointestinal, nausea, vomiting, diarrhea, constipation, consistent with the GLP-1 drug class. The amylin component adds additional GI burden and early reports suggest higher rates of nausea than semaglutide monotherapy. Full safety profile is pending Phase 3 completion.

Is cagrisema FDA approved?

No. As of May 2026, cagrisema remains investigational and under FDA review after Novo filed the NDA in December 2025. REDEFINE-4 later missed non-inferiority versus tirzepatide, so the review story is not just the original REDEFINE-1 efficacy number.

How much does cagrisema cost?

Cagrisema is not yet commercially available; no retail price exists. If approved, pricing is expected to align with branded weight-loss GLP-1 drugs at approximately $1000-1500 per month without insurance. Any vendor versions are gray-market research supply, not equivalent to Novo's dual-chamber clinical product and not a pharmacy workaround.

related peptides

  • semaglutide — the GLP-1 half of cagrisema
  • tirzepatide — competing dual-agonist, beat cagrisema head-to-head in REDEFINE 4
  • retatrutide — triple-agonist next in the queue
  • liraglutide — first-gen GLP-1 that made all this possible

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.